View in EDS

Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers.

Saved in:
Bibliographic Details
Title: Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers.
Authors: Oh, Yumi1,2 (AUTHOR), Jung, Hae Rim1,2 (AUTHOR), Min, Seoyeon3 (AUTHOR), Kang, Jinjoo3 (AUTHOR), Jang, Dongjun4 (AUTHOR), Shin, Seungjae4 (AUTHOR), Kim, Jiwon4 (AUTHOR), Lee, Sang Eun4 (AUTHOR), Sung, Chang Ohk5 (AUTHOR), Lee, Won-Suk6 (AUTHOR), Lee, Charles3,7 (AUTHOR), Jeong, Eui Man1,8,9,10,11 (AUTHOR) emjeong@jejunu.ac.kr, Cho, Sung-Yup1,2,4,12 (AUTHOR) csybio@snu.ac.kr
Source: Cancer Letters. Jan2021, Vol. 497, p123-136. 14p.
Database: Academic Search Ultimate
Description
ISSN:03043835
DOI:10.1016/j.canlet.2020.10.018